Credit Agricole S A Sells 27,279 Shares of IDEXX Laboratories, Inc. $IDXX

Key Points

• Credit Agricole S A has reduced its stake in IDEXX Laboratories by 34.8%, selling 27,279 shares and holding a total of 51,207 shares worth approximately $21.5 million.
• Institutional investors collectively own 87.84% of IDEXX Laboratories, with major investors like Vanguard Group and Principal Financial Group increasing their stakes in the first quarter.
• IDEXX Laboratories recently reported $3.63 EPS, surpassing analysts' estimates, with a revenue of $1.11 billion for the quarter, marking a 10.6% increase year-over-year.

Credit Agricole S A reduced its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 34.8% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 51,207 shares of the company's stock after selling 27,279 shares during the quarter. Credit Agricole S A owned approximately 0.06% of IDEXX Laboratories worth $21,504,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. MorganRosel Wealth Management LLC bought a new position in shares of IDEXX Laboratories in the 1st quarter worth about $26,000. Colonial Trust Co SC lifted its position in shares of IDEXX Laboratories by 84.8% in the 4th quarter. Colonial Trust Co SC now owns 85 shares of the company's stock worth $35,000 after buying an additional 39 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. lifted its position in shares of IDEXX Laboratories by 55.6% in the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 84 shares of the company's stock worth $35,000 after buying an additional 30 shares during the last quarter. Bank of Jackson Hole Trust lifted its position in shares of IDEXX Laboratories by 328.6% in the 1st quarter. Bank of Jackson Hole Trust now owns 90 shares of the company's stock worth $39,000 after buying an additional 69 shares during the last quarter. Finally, Itau Unibanco Holding S.A. lifted its position in shares of IDEXX Laboratories by 540.0% in the 4th quarter. Itau Unibanco Holding S.A. now owns 96 shares of the company's stock worth $40,000 after buying an additional 81 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors.

IDEXX Laboratories Trading Down 0.6%

Shares of IDEXX Laboratories stock traded down $3.9150 during trading on Monday, hitting $641.6350. The stock had a trading volume of 97,052 shares, compared to its average volume of 717,958. The stock has a 50 day simple moving average of $569.94 and a 200 day simple moving average of $494.38. The company has a market capitalization of $51.33 billion, a PE ratio of 53.43, a P/E/G ratio of 4.18 and a beta of 1.49. The company has a quick ratio of 0.79, a current ratio of 1.11 and a debt-to-equity ratio of 0.31. IDEXX Laboratories, Inc. has a 1 year low of $356.14 and a 1 year high of $688.12.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its quarterly earnings results on Monday, August 4th. The company reported $3.63 EPS for the quarter, topping the consensus estimate of $3.28 by $0.35. The business had revenue of $1.11 billion during the quarter, compared to analysts' expectations of $1.06 billion. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The firm's quarterly revenue was up 10.6% compared to the same quarter last year. During the same period last year, the company posted $2.44 earnings per share. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. On average, research analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the stock. Leerink Partners lifted their price objective on shares of IDEXX Laboratories from $580.00 to $600.00 and gave the company an "outperform" rating in a research report on Thursday, July 17th. Stifel Nicolaus set a $640.00 price objective on shares of IDEXX Laboratories in a research report on Monday, August 4th. Jefferies Financial Group assumed coverage on shares of IDEXX Laboratories in a research report on Tuesday, July 1st. They issued a "buy" rating and a $625.00 price objective on the stock. Piper Sandler reiterated a "neutral" rating and issued a $700.00 price objective (up from $510.00) on shares of IDEXX Laboratories in a research report on Monday, August 11th. Finally, Morgan Stanley lifted their price objective on shares of IDEXX Laboratories from $722.00 to $765.00 and gave the company an "overweight" rating in a research report on Friday, August 15th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and three have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $649.44.

Insider Buying and Selling

In other IDEXX Laboratories news, EVP Michael G. Erickson sold 406 shares of the stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $649.96, for a total transaction of $263,883.76. Following the sale, the executive vice president owned 11,287 shares of the company's stock, valued at $7,336,098.52. This represents a 3.47% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Nimrata Hunt sold 1,200 shares of the company's stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $656.53, for a total transaction of $787,836.00. Following the transaction, the executive vice president owned 16,807 shares in the company, valued at approximately $11,034,299.71. The trade was a 6.66% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 51,870 shares of company stock valued at $32,877,757. 0.98% of the stock is owned by company insiders.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.